MeSH term
Frequency | Condition_Probility | Acute Disease | 12 | 0.0 |
Adult | 326 | 0.0 |
Comparative Study | 114 | 0.0 |
Humans | 1481 | 0.0 |
Female | 584 | 0.0 |
Mammography | 2 | 5.0 |
Mutation | 75 | 0.0 |
Animals | 297 | 0.0 |
Research Support, Non-U.S. Gov't | 919 | 0.0 |
Child | 52 | 0.0 |
Male | 425 | 0.0 |
Aged | 321 | 1.0 |
Analysis of Variance | 13 | 0.0 |
Apoptosis/physiology | 31 | 9.0 |
Cohort Studies | 9 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 5 | 3.0 |
Immunohistochemistry/methods | 12 | 1.0 |
Middle Aged | 384 | 0.0 |
Prognosis | 140 | 2.0 |
Protein p53/*analysis | 14 | 7.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis | 52 | 57.0 |
Regression Analysis | 9 | 0.0 |
Disease Progression | 37 | 1.0 |
*Genomic Instability | 3 | 23.0 |
*Microsatellite Repeats | 33 | 14.0 |
*Mutation | 40 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*genetics | 26 | 37.0 |
Receptors, Transforming Growth Factor beta/*genetics | 10 | 23.0 |
History, 20th Century | 3 | 2.0 |
United States | 4 | 0.0 |
Tyrphostins/pharmacology | 2 | 1.0 |
Amino Acid Sequence | 51 | 0.0 |
Amino Acid Substitution | 8 | 0.0 |
Apoptosis | 146 | 8.0 |
Base Sequence | 64 | 0.0 |
Hydrophobicity | 3 | 4.0 |
In Vitro | 14 | 0.0 |
Mitochondria/metabolism | 31 | 12.0 |
Models, Molecular | 12 | 0.0 |
Molecular Sequence Data | 79 | 0.0 |
Mutagenesis, Site-Directed | 10 | 0.0 |
Protein Structure, Secondary | 6 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Aged, 80 and over | 134 | 1.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 3 | 3.0 |
Carrier Proteins/*biosynthesis | 3 | 5.0 |
Cell Movement/physiology | 2 | 0.0 |
Cell Proliferation | 2 | 1.0 |
Genes, bcl-2/physiology | 4 | 33.0 |
Ki-67 Antigen/biosynthesis | 12 | 15.0 |
Neoplasm Staging | 57 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 69 | 49.0 |
Tumor Markers, Biological/*biosynthesis | 7 | 8.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 65 | 60.0 |
Radiation Tolerance/*physiology | 2 | 14.0 |
Statistics | 4 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 8 | 1.0 |
*Apoptosis | 299 | 19.0 |
Caspases/metabolism | 98 | 15.0 |
Cyclophosphamide/therapeutic use | 3 | 3.0 |
Doxorubicin/therapeutic use | 2 | 3.0 |
Fluorouracil/therapeutic use | 2 | 4.0 |
Immunoenzyme Techniques | 48 | 1.0 |
Ki-67 Antigen/metabolism | 15 | 6.0 |
Neoplasm Proteins/*metabolism | 29 | 5.0 |
Proteins/metabolism | 19 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 146 | 33.0 |
Receptor, erbB-2/metabolism | 4 | 2.0 |
Receptors, Estrogen/metabolism | 10 | 3.0 |
Receptors, Progesterone/metabolism | 6 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 52 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 306 | 0.0 |
Tumor Markers, Biological/*metabolism | 19 | 4.0 |
Apoptosis/*genetics | 67 | 27.0 |
Cadmium/*pharmacology | 3 | 21.0 |
Cell Line | 84 | 0.0 |
Cell Line, Transformed | 14 | 0.0 |
Drug Resistance | 8 | 1.0 |
*Gene Expression | 10 | 0.0 |
Cell Differentiation | 24 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 127 | 12.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 110 | 46.0 |
Retrospective Studies | 48 | 1.0 |
Survival Rate | 51 | 2.0 |
Anti-Bacterial Agents/pharmacology | 2 | 1.0 |
Antimetabolites, Antineoplastic/*pharmacology | 9 | 10.0 |
Apoptosis/*drug effects/physiology | 21 | 18.0 |
Blotting, Western | 139 | 2.0 |
Cell Division/drug effects | 65 | 1.0 |
Deoxycytidine/*analogs & derivatives/*pharmacology | 2 | 14.0 |
Drug Resistance, Neoplasm | 30 | 5.0 |
Fluorouracil/*pharmacology | 5 | 12.0 |
Transfection | 88 | 0.0 |
Tumor Cells, Cultured | 310 | 1.0 |
Caspases/physiology | 8 | 14.0 |
Cells, Cultured | 89 | 0.0 |
Cytokines/*pharmacology | 4 | 1.0 |
Proto-Oncogene Proteins/physiology | 11 | 8.0 |
*Proto-Oncogene Proteins c-bcl-2 | 307 | 69.0 |
Apoptosis/*radiation effects | 12 | 29.0 |
Cyclins/*metabolism | 9 | 3.0 |
Dose-Response Relationship, Radiation | 15 | 4.0 |
Protein p53/*metabolism | 52 | 9.0 |
Skin/metabolism/pathology/*radiation effects | 3 | 100.0 |
*Ultraviolet Rays | 6 | 2.0 |
Immunohistochemistry | 298 | 2.0 |
*Muscle Proteins | 2 | 0.0 |
Prostatic Neoplasms/*chemistry/pathology | 2 | 9.0 |
Proto-Oncogene Proteins/analysis | 72 | 37.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 4 | 4.0 |
Apoptosis/*drug effects | 135 | 16.0 |
Down-Regulation/drug effects | 9 | 3.0 |
Proto-Oncogene Proteins/biosynthesis | 72 | 42.0 |
Apoptosis/drug effects | 41 | 6.0 |
Estradiol/*pharmacology | 3 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 18 | 4.0 |
Neoplasm Proteins/biosynthesis/genetics/*physiology | 2 | 4.0 |
*Proteins | 8 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/physiology | 13 | 31.0 |
RNA, Messenger/biosynthesis | 18 | 0.0 |
RNA, Neoplasm/biosynthesis | 4 | 2.0 |
Hyperglycemia/*physiopathology | 2 | 25.0 |
Proto-Oncogene Proteins/genetics | 91 | 16.0 |
Reference Values | 18 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 59 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 3 | 1.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 11 | 10.0 |
Antineoplastic Agents/*pharmacology | 38 | 3.0 |
Bladder Neoplasms/*metabolism/pathology | 2 | 6.0 |
Carrier Proteins/*metabolism | 12 | 1.0 |
Cell Division | 74 | 1.0 |
Cell Membrane/metabolism | 8 | 0.0 |
Cell Nucleus/pathology | 7 | 9.0 |
Cycloheximide/pharmacology | 10 | 1.0 |
Cytochrome c Group/metabolism | 29 | 21.0 |
DNA Fragmentation | 62 | 18.0 |
Dose-Response Relationship, Drug | 82 | 1.0 |
Estrogen Receptor Modulators/*pharmacology | 2 | 8.0 |
In Situ Nick-End Labeling | 109 | 18.0 |
Membrane Potentials | 8 | 3.0 |
Phosphorylation | 29 | 0.0 |
Protein Binding | 30 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 6 | 1.0 |
Time Factors | 93 | 0.0 |
DNA Fragmentation/drug effects | 18 | 19.0 |
Flow Cytometry | 82 | 1.0 |
Indicators and Reagents | 3 | 1.0 |
Tetrazolium Salts/diagnostic use | 2 | 11.0 |
Thiazoles/diagnostic use | 2 | 15.0 |
Caspases/*biosynthesis | 6 | 66.0 |
Apoptosis/drug effects/physiology | 8 | 8.0 |
Down-Regulation/drug effects/physiology | 2 | 5.0 |
Ethanol/*toxicity | 3 | 9.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Mice | 173 | 0.0 |
Mice, Inbred C57BL | 21 | 0.0 |
Antibodies/pharmacology | 2 | 0.0 |
Antigens, CD95/immunology | 3 | 5.0 |
Colonic Neoplasms/genetics/metabolism/pathology | 2 | 25.0 |
Epithelial Cells/metabolism/pathology | 2 | 4.0 |
Membrane Glycoproteins/pharmacology | 7 | 12.0 |
Protein Structure, Tertiary | 24 | 0.0 |
Proto-Oncogene Proteins/biosynthesis/genetics/*physiology | 4 | 16.0 |
Staurosporine/pharmacology | 13 | 6.0 |
Thapsigargin/pharmacology | 2 | 1.0 |
Tumor Necrosis Factor-alpha/pharmacology | 13 | 1.0 |
Neuropeptides/metabolism | 2 | 3.0 |
Proto-Oncogene Proteins/metabolism | 149 | 13.0 |
Apoptosis/*physiology | 121 | 18.0 |
Cell Death/physiology | 4 | 5.0 |
Cell Survival/*physiology | 3 | 5.0 |
Genes, bcl-2/genetics | 16 | 42.0 |
Hydrolysis | 5 | 0.0 |
Rats | 71 | 0.0 |
*Signal Transduction | 6 | 0.0 |
Adenoviruses, Human/genetics | 2 | 4.0 |
Antimetabolites, Antineoplastic/pharmacology | 2 | 2.0 |
Cell Cycle | 28 | 2.0 |
*Cell Cycle Proteins | 11 | 0.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 3 | 3.0 |
DNA Topoisomerases, Type II/antagonists & inhibitors | 2 | 7.0 |
*DNA-Binding Proteins | 23 | 1.0 |
*Drug Resistance, Neoplasm | 13 | 7.0 |
Drug Synergism | 21 | 1.0 |
Enzyme Inhibitors/pharmacology | 37 | 1.0 |
Etoposide/pharmacology | 13 | 8.0 |
Fluorouracil/pharmacology | 3 | 5.0 |
*Gene Therapy | 7 | 1.0 |
Genetic Vectors/genetics | 3 | 1.0 |
Poly(ADP-ribose) Polymerases/metabolism | 27 | 20.0 |
Purines/pharmacology | 3 | 5.0 |
Recombinant Fusion Proteins/physiology | 6 | 2.0 |
Transcription Factors/genetics/*physiology | 3 | 1.0 |
Tumor Cells, Cultured/drug effects/pathology | 2 | 4.0 |
DNA-Binding Proteins/genetics | 18 | 2.0 |
Frameshift Mutation | 12 | 3.0 |
Microsatellite Repeats/*genetics | 41 | 15.0 |
Neoplasm Proteins/analysis | 12 | 3.0 |
Proto-Oncogene Proteins/analysis/genetics | 7 | 25.0 |
Receptor, IGF Type 2/genetics | 18 | 72.0 |
Receptors, Transforming Growth Factor beta/genetics | 26 | 45.0 |
Survival Analysis | 48 | 2.0 |
Transcription Factors/genetics | 8 | 0.0 |
Ki-67 Antigen/analysis | 21 | 7.0 |
Protein p53/biosynthesis | 34 | 24.0 |
Skin/chemistry/pathology | 2 | 8.0 |
Skin Neoplasms/metabolism/*pathology | 2 | 5.0 |
Alleles | 9 | 0.0 |
Colorectal Neoplasms/*genetics | 17 | 7.0 |
Dinucleotide Repeats/genetics | 2 | 4.0 |
Endometrial Neoplasms/*genetics | 5 | 10.0 |
Germ-Line Mutation | 3 | 0.0 |
Neoplasm Proteins/genetics | 16 | 3.0 |
Phosphoric Monoester Hydrolases/genetics | 2 | 2.0 |
Trinucleotide Repeat Expansion | 2 | 5.0 |
Adaptation, Physiological | 2 | 2.0 |
Apoptosis/radiation effects | 3 | 7.0 |
Cyclins/genetics/metabolism | 3 | 5.0 |
Gene Expression/radiation effects | 2 | 10.0 |
Protein p53/genetics/metabolism | 9 | 9.0 |
Radiation Dosage | 2 | 2.0 |
Culture Techniques | 2 | 0.0 |
Genes, p53/*genetics | 24 | 7.0 |
Incidence | 4 | 0.0 |
Ki-67 Antigen/*analysis | 4 | 5.0 |
Microsatellite Repeats | 21 | 1.0 |
Polymerase Chain Reaction/methods | 10 | 0.0 |
Risk Factors | 15 | 0.0 |
Sensitivity and Specificity | 15 | 0.0 |
Tumor Markers, Biological/*analysis | 18 | 1.0 |
English Abstract | 61 | 0.0 |
Membrane Glycoproteins/metabolism | 12 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 9 | 0.0 |
Neurons/drug effects/*metabolism | 2 | 5.0 |
Signal Transduction/*physiology | 6 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 6 | 2.0 |
Proportional Hazards Models | 10 | 1.0 |
Chlorambucil/pharmacology | 2 | 40.0 |
Cyclophosphamide/pharmacology | 2 | 5.0 |
Doxorubicin/pharmacology | 5 | 2.0 |
Drug Screening Assays, Antitumor | 15 | 4.0 |
Glucocorticoids/pharmacology | 2 | 1.0 |
Vidarabine/analogs & derivatives/pharmacology | 2 | 50.0 |
Cytochrome c Group/*metabolism | 14 | 43.0 |
Enzyme Activation/drug effects | 24 | 2.0 |
Mitochondria/drug effects/physiology | 6 | 22.0 |
Protein p53/metabolism | 68 | 11.0 |
Reactive Oxygen Species/metabolism | 8 | 2.0 |
Membrane Glycoproteins/*pharmacology | 12 | 14.0 |
Mice, Inbred BALB C | 11 | 0.0 |
Mice, Nude | 30 | 1.0 |
Receptors, Tumor Necrosis Factor/metabolism | 4 | 2.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 10 | 0.0 |
Base Pair Mismatch/genetics | 6 | 13.0 |
Carcinoma/*genetics | 3 | 2.0 |
Cloning, Molecular | 16 | 0.0 |
DNA Mutational Analysis | 37 | 0.0 |
DNA Repair | 16 | 2.0 |
DNA, Neoplasm/biosynthesis/genetics | 2 | 33.0 |
Genes, p53/genetics | 22 | 9.0 |
Phenotype | 39 | 0.0 |
Thymidine/metabolism | 3 | 0.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Case-Control Studies | 24 | 0.0 |
DNA, Neoplasm/analysis | 17 | 2.0 |
*Genes, cdc | 2 | 9.0 |
Membrane Proteins/genetics | 7 | 1.0 |
*Proto-Oncogene Proteins | 5 | 0.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
Cell Survival | 28 | 2.0 |
DNA, Complementary/metabolism | 10 | 0.0 |
Ovary/metabolism | 2 | 2.0 |
Polymerase Chain Reaction | 65 | 0.0 |
RNA, Messenger/metabolism | 26 | 0.0 |
Fluorescent Antibody Technique, Indirect | 8 | 0.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Antineoplastic Agents/pharmacology | 22 | 4.0 |
Cell Cycle/*drug effects | 11 | 6.0 |
Cell Cycle Proteins/metabolism | 9 | 2.0 |
Cell Survival/drug effects | 34 | 3.0 |
Down-Regulation | 22 | 1.0 |
NF-kappa B/*metabolism | 5 | 0.0 |
Prostatic Neoplasms/metabolism/*pathology | 4 | 5.0 |
Retinoblastoma Protein/metabolism | 6 | 1.0 |
Apoptosis/drug effects/*physiology | 25 | 11.0 |
Hela Cells | 29 | 0.0 |
Hydrogen Peroxide/pharmacology | 4 | 1.0 |
Kinetics | 21 | 0.0 |
Mutagenesis | 4 | 0.0 |
Intracellular Membranes/*metabolism | 4 | 6.0 |
Mitochondria/*physiology | 9 | 17.0 |
Mitochondrial Proteins/metabolism | 2 | 10.0 |
*Viral Proteins | 3 | 1.0 |
Virus Replication | 3 | 0.0 |
Calcium/metabolism | 3 | 0.0 |
Cyclophilins/physiology | 2 | 66.0 |
Ion Channels/*physiology | 2 | 6.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 12 | 13.0 |
Cell Differentiation/drug effects/physiology | 2 | 2.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
HL-60 Cells/cytology/drug effects/metabolism | 2 | 66.0 |
Proto-Oncogene Proteins/metabolism/*physiology | 2 | 4.0 |
Subcellular Fractions/metabolism | 8 | 2.0 |
Cell Division/genetics | 12 | 3.0 |
Disease-Free Survival | 33 | 3.0 |
Drug Resistance, Multiple/*genetics | 2 | 3.0 |
Gene Expression | 52 | 0.0 |
Ki-67 Antigen/biosynthesis/genetics | 3 | 60.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 31 | 36.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/genetics | 21 | 42.0 |
Gene Expression/immunology | 2 | 2.0 |
RNA, Messenger/analysis | 24 | 0.0 |
Pregnancy/*physiology | 2 | 4.0 |
Up-Regulation | 31 | 1.0 |
Adolescent | 73 | 0.0 |
Child, Preschool | 36 | 0.0 |
Microscopy, Electron | 15 | 0.0 |
Rats, Wistar | 12 | 0.0 |
Signal Transduction/physiology | 15 | 1.0 |
Chemotherapy, Adjuvant | 6 | 2.0 |
Protein p53/analysis | 47 | 16.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 69 | 35.0 |
Antigens, CD95/*biosynthesis | 3 | 16.0 |
Apoptosis/*immunology | 8 | 4.0 |
Caspase 1/*biosynthesis | 2 | 100.0 |
Cyclins/biosynthesis | 14 | 14.0 |
Membrane Glycoproteins/*biosynthesis | 3 | 3.0 |
Necrosis | 15 | 4.0 |
Antigens, CD34/analysis | 7 | 1.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 2 | 0.0 |
Immunophenotyping | 4 | 0.0 |
Caspases/*metabolism | 32 | 14.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 26 | 16.0 |
Enzyme Activation | 54 | 1.0 |
*Membrane Proteins | 5 | 0.0 |
Ovarian Neoplasms/*chemistry/pathology | 3 | 23.0 |
Proto-Oncogene Proteins/*analysis | 39 | 24.0 |
Alternative Splicing | 5 | 0.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 2 | 1.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Dimerization | 24 | 1.0 |
Models, Biological | 21 | 0.0 |
Protein Conformation | 17 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/chemistry/metabolism | 3 | 37.0 |
RNA, Messenger/genetics | 14 | 0.0 |
*Chromosome Aberrations | 3 | 0.0 |
Colonic Neoplasms/*genetics/pathology | 2 | 4.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics/pathology | 4 | 40.0 |
DNA, Neoplasm/chemistry/genetics | 4 | 3.0 |
Genetic Heterogeneity | 2 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Karyotyping | 2 | 0.0 |
Ploidies | 8 | 3.0 |
Cell Cycle/drug effects | 29 | 5.0 |
Ovarian Neoplasms/*pathology | 2 | 3.0 |
*Taxoids | 2 | 3.0 |
*Genes, p53 | 36 | 7.0 |
Genotype | 10 | 0.0 |
Multivariate Analysis | 15 | 1.0 |
Proto-Oncogene Proteins/biosynthesis/*genetics | 10 | 16.0 |
Treatment Outcome | 36 | 1.0 |
DNA/metabolism | 3 | 0.0 |
*DNA Damage | 6 | 1.0 |
Helicobacter pylori/*metabolism | 2 | 12.0 |
Oxygen/metabolism | 4 | 1.0 |
*Base Pair Mismatch/genetics | 2 | 66.0 |
*DNA Repair/genetics | 2 | 14.0 |
Infant | 24 | 0.0 |
Trinucleotide Repeat Expansion/genetics | 3 | 7.0 |
Gene Expression Regulation, Neoplastic/genetics | 8 | 4.0 |
Mutation/genetics | 11 | 1.0 |
Syndrome | 2 | 0.0 |
Interleukin-6/*pharmacology | 4 | 1.0 |
Proto-Oncogene Proteins/*biosynthesis | 60 | 38.0 |
Recombinant Proteins/pharmacology | 9 | 0.0 |
Adenoviridae/genetics | 21 | 4.0 |
Amino Acid Motifs | 3 | 0.0 |
Antigens, CD95/metabolism | 22 | 15.0 |
Chromatography, Gel | 2 | 0.0 |
Precipitin Tests | 22 | 0.0 |
Proto-Oncogene Proteins/chemistry/metabolism | 2 | 13.0 |
Recombinant Fusion Proteins/metabolism | 9 | 0.0 |
Two-Hybrid System Techniques | 5 | 0.0 |
Cell Hypoxia | 4 | 2.0 |
Statistics, Nonparametric | 6 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 7 | 7.0 |
Cell Division/*drug effects | 2 | 0.0 |
Jurkat Cells | 21 | 1.0 |
Thiocyanates/*pharmacology | 2 | 16.0 |
*Apoptosis/genetics | 18 | 50.0 |
Mouth Neoplasms/*chemistry | 2 | 28.0 |
*Gene Expression Regulation, Neoplastic | 35 | 2.0 |
Cell Cycle/drug effects/radiation effects | 4 | 21.0 |
Gene Expression Regulation, Neoplastic/*radiation effects | 3 | 14.0 |
Gene Transfer Techniques | 9 | 1.0 |
Breast Neoplasms | 7 | 2.0 |
Immunoblotting | 34 | 1.0 |
Antigens, Nuclear | 7 | 4.0 |
Ki-67 Antigen | 6 | 2.0 |
Nuclear Proteins/analysis | 3 | 1.0 |
Predictive Value of Tests | 23 | 1.0 |
Proliferating Cell Nuclear Antigen/analysis | 12 | 4.0 |
Drug Stability | 2 | 0.0 |
Microscopy, Fluorescence | 28 | 1.0 |
Protein Conformation/drug effects | 3 | 5.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
Temperature | 5 | 0.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Interleukin-4/metabolism | 2 | 2.0 |
*Intracellular Signaling Peptides and Proteins | 12 | 1.0 |
Ligands | 20 | 0.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Monocytes/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/*metabolism | 2 | 40.0 |
*Up-Regulation | 5 | 2.0 |
Protein p53/*biosynthesis/genetics | 7 | 18.0 |
Proto-Oncogene Proteins/*biosynthesis/genetics | 26 | 29.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis/genetics | 20 | 58.0 |
Carrier Proteins/*genetics | 6 | 0.0 |
Chromosome Mapping | 8 | 0.0 |
Chromosomes, Human, Pair 19/*genetics | 2 | 2.0 |
Genes, Dominant | 3 | 0.0 |
Pedigree | 7 | 0.0 |
Proto-Oncogene Proteins/*genetics/metabolism/radiation effects | 2 | 100.0 |
Kidney/cytology | 3 | 1.0 |
COS Cells | 13 | 0.0 |
Carrier Proteins/*chemistry/metabolism | 3 | 7.0 |
Membrane Proteins/*metabolism | 9 | 1.0 |
Microscopy, Confocal | 19 | 1.0 |
Mitochondria, Liver/metabolism | 2 | 13.0 |
Plasmids/metabolism | 9 | 0.0 |
Recombinant Proteins/metabolism | 16 | 0.0 |
Gastrointestinal Neoplasms/*genetics | 3 | 9.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Protein p53/physiology | 6 | 7.0 |
Camptothecin/*pharmacology | 4 | 11.0 |
Cisplatin/*pharmacology | 15 | 11.0 |
Cytochrome c Group/secretion | 7 | 50.0 |
*Papillomavirus, Human | 3 | 9.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Tumor Suppressor Proteins/metabolism | 6 | 5.0 |
Caspases/genetics/*metabolism | 3 | 20.0 |
Chromosome Deletion | 2 | 0.0 |
DNA Primers/chemistry | 13 | 1.0 |
Loss of Heterozygosity | 16 | 1.0 |
Proteins/genetics/*metabolism | 6 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/metabolism | 14 | 25.0 |
Transcription, Genetic | 18 | 0.0 |
Transduction, Genetic | 8 | 2.0 |
Cell Transformation, Neoplastic | 6 | 1.0 |
Codon | 6 | 1.0 |
*Promoter Regions (Genetics) | 6 | 0.0 |
Response Elements | 2 | 0.0 |
Trans-Activation (Genetics) | 10 | 0.0 |
Breast Neoplasms/genetics/metabolism/*pathology | 2 | 5.0 |
Cell Cycle Proteins/*metabolism | 6 | 1.0 |
Colorectal Neoplasms/*metabolism/pathology | 3 | 6.0 |
Neoplasm Proteins/metabolism | 23 | 5.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols | 3 | 10.0 |
Caspases/antagonists & inhibitors/metabolism | 9 | 11.0 |
Combined Modality Therapy | 29 | 2.0 |
Signal Transduction/*drug effects | 4 | 1.0 |
Tumor Cells, Cultured/drug effects | 15 | 2.0 |
Antineoplastic Agents/*toxicity | 5 | 7.0 |
Cisplatin/*toxicity | 4 | 18.0 |
Proto-Oncogene Proteins/analysis/*metabolism | 2 | 25.0 |
Rats, Sprague-Dawley | 16 | 0.0 |
Signal Transduction | 27 | 0.0 |
*Apoptosis/physiology | 3 | 37.0 |
Chronic Disease | 6 | 0.0 |
Epithelial Cells/pathology | 2 | 2.0 |
Cell Line, Tumor | 60 | 2.0 |
Proteomics | 2 | 6.0 |
Leukocyte Count | 2 | 0.0 |
Plasmids/genetics | 3 | 0.0 |
Transplantation, Heterologous | 12 | 1.0 |
Blotting, Western/methods | 5 | 2.0 |
Cell Survival/physiology | 7 | 3.0 |
Cytochromes c/*metabolism | 5 | 55.0 |
DNA Mutational Analysis/methods | 4 | 1.0 |
*Gene Expression Regulation | 13 | 0.0 |
Neuroblastoma | 2 | 1.0 |
Caspases/antagonists & inhibitors/*metabolism | 8 | 14.0 |
Lactones/*pharmacology | 2 | 6.0 |
Oligopeptides/pharmacology | 9 | 5.0 |
DNA, Neoplasm/*genetics | 8 | 3.0 |
Lymphatic Metastasis | 19 | 1.0 |
*Neovascularization, Pathologic | 3 | 0.0 |
Protein p53/*biosynthesis | 17 | 14.0 |
Radiotherapy, Adjuvant | 3 | 3.0 |
Vascular Endothelial Growth Factor A | 6 | 0.0 |
Vascular Endothelial Growth Factors | 6 | 0.0 |
Neoplasms/drug therapy/*metabolism | 3 | 17.0 |
Antineoplastic Agents, Phytogenic/*therapeutic use | 3 | 9.0 |
Dose Fractionation | 2 | 11.0 |
Paclitaxel/*therapeutic use | 3 | 20.0 |
Radiation-Sensitizing Agents/*therapeutic use | 2 | 28.0 |
Receptor, erbB-2/analysis | 5 | 5.0 |
Caspases/*genetics/metabolism | 3 | 50.0 |
Gene Expression/physiology | 4 | 1.0 |
Protein p53/*genetics/metabolism | 4 | 10.0 |
Proteins/*genetics/metabolism | 3 | 1.0 |
Antibiotics, Antineoplastic/*pharmacology | 5 | 4.0 |
Mitomycin/*pharmacology | 2 | 8.0 |
Receptors, Tumor Necrosis Factor/*metabolism | 4 | 1.0 |
Membrane Proteins/genetics/*metabolism | 3 | 1.0 |
Neoplasm Proteins/genetics/metabolism | 3 | 2.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 25 | 6.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism | 27 | 46.0 |
Gene Expression Regulation, Neoplastic | 47 | 2.0 |
Annexin A5/metabolism | 9 | 10.0 |
Antigens, CD95/analysis | 12 | 36.0 |
DNA/analysis | 5 | 0.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
*Adaptor Proteins, Signal Transducing | 7 | 0.0 |
Carrier Proteins/metabolism | 17 | 2.0 |
Electrophoresis, Agar Gel | 6 | 1.0 |
Ovarian Neoplasms/*metabolism | 5 | 8.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
Carcinoma, Squamous Cell/*drug therapy/pathology | 2 | 20.0 |
Gene Expression/drug effects | 12 | 1.0 |
Mitochondria/drug effects/metabolism | 5 | 15.0 |
Proto-Oncogene Proteins/genetics/metabolism | 13 | 7.0 |
Arteriosclerosis/*pathology | 4 | 14.0 |
Biological Markers/analysis | 13 | 1.0 |
Coronary Vessels/pathology | 2 | 4.0 |
Endarterectomy, Carotid | 2 | 15.0 |
Membrane Proteins/*analysis | 8 | 11.0 |
Cell Cycle/drug effects/physiology | 2 | 3.0 |
Inhibitory Concentration 50 | 4 | 1.0 |
Proto-Oncogene Proteins/biosynthesis/physiology | 4 | 44.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/physiology | 2 | 50.0 |
Genes, ras | 4 | 1.0 |
Colon/pathology | 2 | 4.0 |
Colorectal Neoplasms/*genetics/pathology | 8 | 9.0 |
Genes, APC | 2 | 2.0 |
Genes, p53 | 24 | 5.0 |
B-Lymphocytes/*metabolism | 3 | 1.0 |
Membrane Proteins/*biosynthesis | 5 | 8.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
Thymus Gland/cytology | 3 | 3.0 |
Breast Neoplasms/*metabolism | 5 | 1.0 |
Curcumin/*pharmacology | 3 | 12.0 |
Conserved Sequence | 2 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Genes, Reporter | 10 | 0.0 |
*Introns | 2 | 0.0 |
Protein p53/*physiology | 12 | 9.0 |
Sequence Alignment | 11 | 0.0 |
*Trans-Activation (Genetics) | 8 | 1.0 |
Gene Therapy | 7 | 2.0 |
Genes, Tumor Suppressor | 9 | 1.0 |
Genetic Vectors | 22 | 1.0 |
*Interleukins | 5 | 100.0 |
Protein p53/genetics/physiology | 2 | 8.0 |
RNA/analysis | 2 | 0.0 |
Gene Therapy/*methods | 10 | 2.0 |
Genetic Vectors/administration & dosage | 2 | 6.0 |
Mice, Inbred C3H | 8 | 1.0 |
Models, Animal | 3 | 1.0 |
Proto-Oncogene Proteins/*genetics | 60 | 6.0 |
Bleomycin/pharmacology | 2 | 7.0 |
Protein p53/genetics | 15 | 9.0 |
Topotecan/*pharmacology | 2 | 40.0 |
Antigens, CD34/biosynthesis | 2 | 2.0 |
Endothelium, Vascular/metabolism | 2 | 0.0 |
*Drug Resistance, Multiple | 3 | 2.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Proteins/*metabolism | 7 | 0.0 |
Proto-Oncogene Proteins/*analysis/genetics | 8 | 25.0 |
Chromones/pharmacology | 7 | 3.0 |
Cytoplasm/metabolism | 8 | 0.0 |
Green Fluorescent Proteins | 8 | 0.0 |
Luminescent Proteins/metabolism | 3 | 0.0 |
Mitochondria/*metabolism | 21 | 12.0 |
Morpholines/pharmacology | 7 | 2.0 |
Protein Transport | 20 | 3.0 |
*Protein-Serine-Threonine Kinases | 15 | 1.0 |
Apoptosis/*drug effects/genetics | 9 | 28.0 |
Caspases/biosynthesis/genetics | 5 | 50.0 |
Cyclins/biosynthesis/genetics | 8 | 16.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Gene Expression Profiling | 6 | 0.0 |
Genes, bcl-2 | 33 | 32.0 |
Neoplasm Proteins/*biosynthesis/genetics | 8 | 4.0 |
*Nuclear Proteins | 28 | 1.0 |
Life Tables | 3 | 1.0 |
Neoplasm Proteins/*genetics | 6 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 39 | 38.0 |
Biopsy | 21 | 1.0 |
Follow-Up Studies | 17 | 0.0 |
Reed-Sternberg Cells/*metabolism | 2 | 16.0 |
Computer Simulation | 2 | 0.0 |
*Models, Biological | 2 | 1.0 |
Liver/*metabolism | 2 | 0.0 |
*Carcinoma, Hepatocellular | 2 | 12.0 |
Cyclins/metabolism | 28 | 6.0 |
Enzyme Inhibitors/*pharmacology | 15 | 2.0 |
Histone Deacetylases/*antagonists & inhibitors | 2 | 4.0 |
Hydroxamic Acids/*pharmacology | 2 | 4.0 |
*Liver Neoplasms | 2 | 10.0 |
Tumor Cells, Cultured/cytology/drug effects/enzymology | 2 | 12.0 |
Lymphatic Metastasis/genetics | 2 | 7.0 |
Neoplasm Metastasis/*genetics | 2 | 3.0 |
Loss of Heterozygosity/*genetics | 2 | 2.0 |
Stomach Neoplasms/*genetics/pathology | 6 | 12.0 |
Membrane Proteins/metabolism | 18 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 9 | 1.0 |
Neoplasm Invasiveness | 21 | 1.0 |
Neoplasm Recurrence, Local | 14 | 3.0 |
*Preoperative Care | 2 | 10.0 |
Bone Marrow/pathology | 3 | 0.0 |
Lymph Nodes/pathology | 3 | 1.0 |
Magnetic Resonance Imaging/*methods | 3 | 4.0 |
Breast Neoplasms/*diagnosis | 2 | 11.0 |
Risk Assessment | 5 | 0.0 |
HL-60 Cells | 22 | 3.0 |
Base Pair Mismatch | 12 | 7.0 |
Carcinoma/*genetics/pathology | 7 | 11.0 |
DNA Methylation | 6 | 0.0 |
Endometrial Neoplasms/*genetics/pathology | 6 | 18.0 |
*Genes, ras | 2 | 0.0 |
Neoplasm Proteins | 3 | 9.0 |
*Gene Expression Profiling | 4 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/analysis/*biosynthesis | 8 | 72.0 |
Cell Cycle Proteins/physiology | 2 | 5.0 |
*MAP Kinase Kinase Kinase 1 | 3 | 2.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Proteasome Endopeptidase Complex | 6 | 1.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
Apoptosis/genetics/*physiology | 10 | 27.0 |
Cross-Linking Reagents/pharmacology | 4 | 2.0 |
Cytosol/metabolism | 14 | 2.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Subcellular Fractions | 5 | 2.0 |
Tumor Necrosis Factor-alpha/metabolism | 4 | 0.0 |
Cysteine Endopeptidases/drug effects/*metabolism | 2 | 20.0 |
Cysteine Proteinase Inhibitors/pharmacology | 19 | 8.0 |
DNA Fragmentation/drug effects/physiology | 2 | 33.0 |
Evolution | 2 | 0.0 |
Mitochondria/physiology | 10 | 16.0 |
Permeability/drug effects | 2 | 8.0 |
Poly(ADP-ribose) Polymerases/drug effects/metabolism | 2 | 100.0 |
Proto-Oncogene Proteins/pharmacology | 2 | 9.0 |
Staurosporine/*pharmacology | 2 | 10.0 |
Paraffin Embedding | 3 | 1.0 |
Antibodies, Monoclonal | 5 | 0.0 |
In Situ Nick-End Labeling/methods | 7 | 28.0 |
Endometrial Neoplasms/*metabolism/pathology | 2 | 6.0 |
Hyperplasia/genetics | 3 | 14.0 |
Carrier Proteins/genetics/*metabolism | 4 | 0.0 |
Mitochondria/genetics/metabolism | 2 | 40.0 |
Animals, Newborn | 4 | 0.0 |
Disease Models, Animal | 13 | 0.0 |
Fluorescent Dyes/metabolism | 3 | 4.0 |
Mice, Transgenic | 13 | 0.0 |
Cell Cycle Proteins/*analysis | 2 | 11.0 |
Enzyme Inhibitors/*analysis | 2 | 16.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 5 | 9.0 |
Drug Resistance, Neoplasm/physiology | 2 | 13.0 |
Genes, MDR | 2 | 6.0 |
Tamoxifen/*pharmacology | 3 | 4.0 |
Antigens, CD95/biosynthesis/genetics | 3 | 37.0 |
Carcinoma, Squamous Cell/pathology | 2 | 4.0 |
*Gamma Rays | 4 | 9.0 |
Mice, Inbred Strains | 7 | 0.0 |
Radiation Tolerance | 5 | 5.0 |
Signal Transduction/*radiation effects | 2 | 10.0 |
Spleen/cytology/metabolism/radiation effects | 2 | 100.0 |
*X-Rays | 2 | 20.0 |
Pregnancy | 28 | 0.0 |
Drug Resistance, Neoplasm/genetics | 6 | 8.0 |
*Transduction, Genetic | 3 | 4.0 |
Vincristine/*pharmacology | 2 | 18.0 |
Adenocarcinoma/mortality/*pathology | 2 | 40.0 |
*Apoptosis/drug effects | 13 | 11.0 |
Neoplasms/pathology | 2 | 7.0 |
Paclitaxel/pharmacology | 3 | 3.0 |
Phosphorylation/drug effects | 9 | 1.0 |
CDC2 Protein Kinase/metabolism | 2 | 1.0 |
Flavonoids/pharmacology | 6 | 1.0 |
Imidazoles/pharmacology | 3 | 1.0 |
Indoles/pharmacology | 3 | 1.0 |
Maleimides/pharmacology | 2 | 2.0 |
Microtubules/*drug effects | 2 | 10.0 |
Nocodazole/*pharmacology | 2 | 22.0 |
Peptidylprolyl Isomerase/*metabolism | 2 | 13.0 |
Proline/chemistry | 2 | 4.0 |
Protein Kinase Inhibitors | 4 | 3.0 |
Pyridines/pharmacology | 3 | 1.0 |
Structure-Activity Relationship | 8 | 0.0 |
Carrier Proteins/analysis/*biosynthesis | 2 | 22.0 |
Enzyme-Linked Immunosorbent Assay | 14 | 0.0 |
Protein-Serine-Threonine Kinases/analysis/*biosynthesis | 2 | 40.0 |
Proto-Oncogene Proteins/analysis/biosynthesis | 5 | 38.0 |
Proto-Oncogene Proteins c-bcl-2/analysis/biosynthesis | 4 | 50.0 |
DNA Damage | 13 | 1.0 |
Protein Biosynthesis | 12 | 0.0 |
Protein p53/analysis/*physiology | 2 | 22.0 |
Treatment Failure | 2 | 0.0 |
*Multidrug Resistance-Associated Proteins | 14 | 25.0 |
Ovarian Neoplasms/*genetics/pathology | 3 | 3.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Interleukin-3/pharmacology | 3 | 1.0 |
Binding Sites | 19 | 0.0 |
Cyclooxygenase Inhibitors/pharmacology | 3 | 4.0 |
Indomethacin/pharmacology | 3 | 1.0 |
Peptides/chemistry | 5 | 1.0 |
Antineoplastic Agents/*therapeutic use | 9 | 2.0 |
Isoenzymes/analysis | 3 | 5.0 |
Prostaglandin-Endoperoxide Synthase/analysis | 2 | 25.0 |
*Trans-Activators | 6 | 0.0 |
Tumor Markers, Biological/analysis | 17 | 2.0 |
Doxorubicin/*pharmacology | 3 | 4.0 |
Drug Resistance, Neoplasm/*physiology | 2 | 6.0 |
Multiple Myeloma/*pathology | 3 | 5.0 |
*Base Pair Mismatch | 5 | 5.0 |
*DNA Repair | 10 | 1.0 |
Exons | 13 | 0.0 |
Lymphocytes/metabolism | 3 | 1.0 |
Microsatellite Repeats/genetics | 7 | 1.0 |
Poly A | 3 | 21.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Blotting, Northern | 18 | 0.0 |
Fibroblasts/metabolism | 5 | 0.0 |
Adenocarcinoma/*pathology | 2 | 2.0 |
Apoptosis/drug effects/radiation effects | 5 | 31.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Neoplasm Proteins/biosynthesis/genetics | 6 | 4.0 |
Protein Processing, Post-Translational/drug effects | 3 | 2.0 |
Protein-Serine-Threonine Kinases/metabolism | 5 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism/radiation effects | 2 | 18.0 |
Tumor Stem Cell Assay | 6 | 3.0 |
Tyrphostins/*pharmacology | 2 | 8.0 |
Cell Differentiation/drug effects | 7 | 0.0 |
Membrane Potentials/drug effects | 10 | 7.0 |
Stilbenes/*pharmacology | 4 | 7.0 |
Polymorphism, Single-Stranded Conformational | 25 | 1.0 |
Apoptosis/*genetics/*physiology | 2 | 22.0 |
Cell Death/*physiology | 3 | 7.0 |
G2 Phase/physiology | 2 | 7.0 |
Mitochondria/metabolism/ultrastructure | 5 | 45.0 |
Mitosis/physiology | 3 | 3.0 |
Cattle | 7 | 0.0 |
Meat/*microbiology | 2 | 33.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Cell Division/*genetics | 2 | 3.0 |
Genes, myc | 3 | 1.0 |
Mice, Knockout | 13 | 0.0 |
Lung Neoplasms/*pathology | 3 | 4.0 |
NF-kappa B/metabolism | 7 | 0.0 |
Triterpenes/*pharmacology | 4 | 50.0 |
Antineoplastic Agents, Phytogenic/pharmacokinetics/*pharmacology | 2 | 50.0 |
Ovarian Neoplasms/*drug therapy/metabolism/pathology | 2 | 40.0 |
RNA, Messenger/biosynthesis/genetics | 6 | 1.0 |
Cervix Neoplasms/*metabolism/pathology/*radiotherapy | 2 | 50.0 |
DNA-Binding Proteins/*genetics | 5 | 0.0 |
Frameshift Mutation/genetics | 4 | 5.0 |
Germ-Line Mutation/*genetics | 3 | 1.0 |
Intestinal Mucosa/pathology | 4 | 7.0 |
Mutation/*genetics | 14 | 1.0 |
Apoptosis/genetics | 31 | 13.0 |
Cell Cycle/genetics | 5 | 3.0 |
Ovarian Neoplasms/*genetics/metabolism/pathology | 2 | 6.0 |
Protein p53/biosynthesis/genetics | 8 | 16.0 |
Prostatic Neoplasms/pathology/*therapy | 2 | 40.0 |
Antibodies, Monoclonal/metabolism | 5 | 1.0 |
Cell Separation | 4 | 0.0 |
Lymphoma, B-Cell/*metabolism | 2 | 15.0 |
Cell Division/physiology | 16 | 1.0 |
Cell Nucleus/metabolism | 12 | 0.0 |
*JNK Mitogen-Activated Protein Kinases | 2 | 2.0 |
Mitotic Index | 6 | 3.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
DNA Repair/genetics | 7 | 4.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Arsenicals/*pharmacology | 3 | 11.0 |
Oxides/*pharmacology | 3 | 13.0 |
Protein-Tyrosine Kinase/metabolism | 4 | 0.0 |
Ovarian Neoplasms/*genetics | 3 | 0.0 |
Protein p53/analysis/*biosynthesis | 2 | 9.0 |
Proto-Oncogene Proteins/analysis/*biosynthesis | 9 | 37.0 |
Kidney/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/immunology/*metabolism | 3 | 21.0 |
Proto-Oncogene Proteins c-bcl-2/immunology/*metabolism | 3 | 60.0 |
Butyrates/pharmacology | 2 | 5.0 |
Histone Deacetylases/*antagonists & inhibitors/metabolism | 2 | 13.0 |
DNA, Neoplasm/analysis/genetics | 2 | 2.0 |
Diploidy | 3 | 2.0 |
Neoplasm Metastasis | 12 | 1.0 |
Proto-Oncogene Proteins/genetics/physiology | 3 | 9.0 |
Adenoma/metabolism/pathology | 2 | 7.0 |
Alkaloids/*pharmacology | 2 | 3.0 |
Apoptosis/*drug effects/radiation effects | 3 | 23.0 |
Drug Combinations | 2 | 0.0 |
Enzyme Activation/drug effects/radiation effects | 3 | 33.0 |
Membrane Potentials/drug effects/radiation effects | 2 | 50.0 |
Camptothecin/pharmacology | 5 | 10.0 |
DNA Topoisomerases, Type I/antagonists & inhibitors | 6 | 24.0 |
Cell Lineage | 2 | 0.0 |
Cisplatin/pharmacology | 12 | 7.0 |
Epitopes | 2 | 0.0 |
Neuroblastoma/metabolism | 2 | 3.0 |
Caspases/analysis | 6 | 30.0 |
Fixatives | 2 | 2.0 |
Formaldehyde | 2 | 2.0 |
Frozen Sections | 2 | 2.0 |
Membrane Proteins/analysis | 4 | 3.0 |
Motor Neurons/*pathology | 2 | 10.0 |
Polymers | 2 | 1.0 |
Spinal Cord/pathology | 2 | 2.0 |
Antigens, CD95/physiology | 3 | 4.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Etoposide/toxicity | 3 | 17.0 |
Sequence Deletion | 14 | 0.0 |
U937 Cells | 7 | 1.0 |
Apoptosis/drug effects/*genetics | 6 | 18.0 |
DNA-Binding Proteins/biosynthesis/genetics | 2 | 2.0 |
Dactinomycin/pharmacology | 4 | 1.0 |
Gene Expression Regulation/drug effects | 15 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 6 | 1.0 |
Half-Life | 2 | 0.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Membrane Proteins/biosynthesis/genetics | 2 | 5.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Proteins/genetics | 13 | 1.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Transcription, Genetic/drug effects | 6 | 0.0 |
Antigens, CD95/*metabolism | 10 | 8.0 |
Cytosol/enzymology | 2 | 1.0 |
Membrane Glycoproteins/*metabolism | 6 | 1.0 |
Mitochondria/enzymology | 4 | 3.0 |
Adenoviridae | 6 | 6.0 |
Carrier Proteins/genetics/metabolism | 3 | 1.0 |
Cell Division/drug effects/genetics | 4 | 4.0 |
Cell Movement/drug effects | 2 | 0.0 |
Proto-Oncogene Protein p21(ras)/metabolism | 3 | 3.0 |
Apoptosis/drug effects/genetics/*physiology | 6 | 30.0 |
Chromosomes, Human, Pair 15/genetics | 2 | 2.0 |
Intracellular Membranes/physiology | 2 | 7.0 |
Membrane Potentials/physiology | 2 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/*physiology | 4 | 44.0 |
Sequence Analysis, DNA | 8 | 0.0 |
Sequence Homology, Amino Acid | 16 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Phosphoric Monoester Hydrolases/*genetics | 5 | 2.0 |
Epithelial Cells/drug effects/metabolism/pathology | 2 | 66.0 |
Tumor Cells, Cultured/drug effects/metabolism/pathology | 4 | 10.0 |
DNA Primers | 23 | 0.0 |
*Frameshift Mutation | 23 | 12.0 |
Proto-Oncogene Proteins/chemistry/genetics | 2 | 25.0 |
Carrier Proteins/metabolism/pharmacology | 2 | 18.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Membrane Glycoproteins/metabolism/pharmacology | 2 | 50.0 |
Up-Regulation/drug effects | 6 | 1.0 |
Esophagus/metabolism/pathology | 2 | 28.0 |
Liver/metabolism | 2 | 0.0 |
Neoplasms, Multiple Primary/*genetics | 2 | 5.0 |
Stomach Neoplasms/*genetics/metabolism | 2 | 7.0 |
*Protein Biosynthesis | 6 | 1.0 |
Proteins/analysis | 2 | 1.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Aging/physiology | 3 | 1.0 |
Cyclin D1/*biosynthesis | 2 | 10.0 |
Cyclins/*biosynthesis | 3 | 5.0 |
Infant, Newborn | 13 | 0.0 |
Ki-67 Antigen/*biosynthesis | 2 | 7.0 |
Liver/*drug effects/pathology | 2 | 22.0 |
Progesterone/blood | 3 | 1.0 |
In Situ Hybridization | 16 | 0.0 |
Adenocarcinoma, Mucinous/genetics/pathology | 2 | 50.0 |
Endometrial Hyperplasia/genetics/pathology | 2 | 100.0 |
*Genes, bcl-2 | 19 | 29.0 |
Proto-Oncogene Proteins/analysis/*genetics | 11 | 23.0 |
Proto-Oncogene Proteins c-bcl-2/analysis/genetics | 6 | 37.0 |
Endothelium, Vascular/*cytology/drug effects | 2 | 4.0 |
Proto-Oncogene Proteins/analysis/metabolism | 4 | 66.0 |
Proto-Oncogene Proteins c-bcl-2/analysis/metabolism | 5 | 83.0 |
Umbilical Veins | 2 | 0.0 |
Fungal Proteins/*genetics | 2 | 1.0 |
Gene Deletion | 10 | 0.0 |
Reproducibility of Results | 6 | 0.0 |
*Trinucleotide Repeat Expansion | 3 | 6.0 |
Transcription Factors/*genetics/metabolism | 3 | 0.0 |
Tumor Markers, Biological | 6 | 1.0 |
Adenocarcinoma/*genetics/pathology | 3 | 3.0 |
Gene Silencing | 2 | 0.0 |
*Tumor Suppressor Proteins | 14 | 1.0 |
Antigens, CD95/genetics | 9 | 39.0 |
Epithelial Cells/drug effects/metabolism | 2 | 2.0 |
Membrane Glycoproteins/genetics | 3 | 1.0 |
Receptors, Tumor Necrosis Factor/genetics | 2 | 4.0 |
Membrane Glycoproteins/analysis | 7 | 2.0 |
Proto-Oncogene Proteins c-myc/analysis | 2 | 11.0 |
Carcinoma, Squamous Cell/genetics/*metabolism | 2 | 10.0 |
Hyperplasia | 9 | 2.0 |
Staining and Labeling | 9 | 1.0 |
Carcinoma, Squamous Cell/*genetics | 3 | 1.0 |
Head and Neck Neoplasms/*genetics | 3 | 4.0 |
Tretinoin/*pharmacology/therapeutic use | 3 | 21.0 |
Cell Death | 17 | 5.0 |
Rabbits | 7 | 0.0 |
Brain/metabolism/pathology | 3 | 2.0 |
Flavoproteins/metabolism | 3 | 20.0 |
Mitochondria/*metabolism/pathology | 2 | 50.0 |
Neurons/*metabolism/pathology | 2 | 3.0 |
Proto-Oncogene Proteins/drug effects/genetics/metabolism | 2 | 28.0 |
Protein p53/genetics/*metabolism | 13 | 6.0 |
Cyclins/*analysis | 2 | 5.0 |
Caspases/biosynthesis | 9 | 52.0 |
Drug Interactions | 5 | 0.0 |
Enzyme Induction | 2 | 0.0 |
Isoenzymes/metabolism | 4 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
*Arabidopsis Proteins | 2 | 2.0 |
DNA-Binding Proteins/*metabolism | 6 | 0.0 |
Promoter Regions (Genetics) | 19 | 0.0 |
Receptors, Androgen/*metabolism | 3 | 2.0 |
Transcription Factors/*metabolism | 5 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
ADP-ribosyl Cyclase | 2 | 0.0 |
*Antigens, CD | 2 | 0.0 |
Carrier Proteins/drug effects/metabolism | 4 | 26.0 |
Proto-Oncogene Proteins/drug effects/metabolism | 9 | 29.0 |
Proto-Oncogene Proteins c-bcl-2/drug effects/*metabolism | 2 | 100.0 |
Transforming Growth Factor beta/*pharmacology | 6 | 1.0 |
Cell Cycle/radiation effects | 4 | 14.0 |
Bronchoscopy | 2 | 3.0 |
Biological Transport | 10 | 0.0 |
Etoposide/*pharmacology | 6 | 19.0 |
K562 Cells | 11 | 2.0 |
Caspases/antagonists & inhibitors | 2 | 4.0 |
MAP Kinase Kinase 1 | 3 | 1.0 |
MAP Kinase Signaling System/drug effects | 3 | 3.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 3 | 3.0 |
Stem Cell Factor/*pharmacology | 2 | 3.0 |
Biopsy, Needle | 7 | 1.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 2 | 14.0 |
Confidence Intervals | 2 | 0.0 |
Genes, bcl-2/*genetics | 10 | 38.0 |
Genetic Markers/genetics | 2 | 0.0 |
Laryngeal Neoplasms/*genetics/mortality/pathology | 2 | 40.0 |
Probability | 4 | 0.0 |
DNA Nucleotidylexotransferase/analysis | 2 | 10.0 |
Glial Fibrillary Acidic Protein/analysis | 3 | 1.0 |
Phosphopyruvate Hydratase/analysis | 2 | 2.0 |
Cytoplasm/pathology | 3 | 11.0 |
*Proteasome Endopeptidase Complex | 2 | 3.0 |
Xenograft Model Antitumor Assays | 6 | 2.0 |
Cytarabine/pharmacology | 4 | 8.0 |
Drug Resistance, Multiple | 6 | 3.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
*Antigens, Bacterial | 3 | 5.0 |
Cytokines/blood | 2 | 0.0 |
*Helicobacter pylori | 2 | 1.0 |
Tumor Necrosis Factor-alpha/analysis | 3 | 0.0 |
Ceramides/pharmacology | 2 | 6.0 |
Densitometry | 3 | 2.0 |
*Melanoma | 2 | 25.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis/genetics | 4 | 50.0 |
Cyclin D1/biosynthesis | 4 | 9.0 |
Antigens, CD95/biosynthesis | 5 | 17.0 |
Cytokines/pharmacology | 4 | 1.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/analysis/*genetics | 8 | 72.0 |
Base Pair Mismatch/*genetics | 3 | 5.0 |
DNA Repair/*genetics | 6 | 1.0 |
Transforming Growth Factor beta/*genetics | 2 | 2.0 |
Cyclins/analysis | 3 | 7.0 |
Neoplasm Proteins/*analysis | 8 | 2.0 |
Retinoblastoma Protein/analysis | 3 | 8.0 |
Biological Markers | 7 | 0.0 |
Endometrial Neoplasms/metabolism/*pathology | 2 | 20.0 |
Neoplasm Proteins/biosynthesis | 6 | 7.0 |
Carcinoma, Squamous Cell/metabolism/*pathology | 3 | 11.0 |
Plant Extracts/*pharmacology | 3 | 4.0 |
Proto-Oncogene Proteins c-bcl-2/analysis/*metabolism | 3 | 60.0 |
Protein p53/genetics/*physiology | 2 | 5.0 |
Radiation, Ionizing | 4 | 2.0 |
Vincristine/pharmacology | 3 | 5.0 |
Caspases/*drug effects/metabolism | 3 | 100.0 |
Proto-Oncogene Proteins/*drug effects/metabolism | 2 | 50.0 |
Proto-Oncogene Proteins c-bcl-2/*drug effects/metabolism | 2 | 100.0 |
Golgi Apparatus/metabolism/ultrastructure | 2 | 12.0 |
Isoenzymes/antagonists & inhibitors | 2 | 4.0 |
Microscopy, Immunoelectron | 4 | 0.0 |
Nuclear Envelope/metabolism/ultrastructure | 2 | 25.0 |
Prostaglandin-Endoperoxide Synthase | 4 | 13.0 |
Translocation, Genetic | 5 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Recombinant Proteins/biosynthesis | 5 | 1.0 |
Intracellular Membranes/metabolism/ultrastructure | 2 | 50.0 |
Microscopy, Electron/methods | 2 | 3.0 |
Endometrium/*metabolism | 2 | 2.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 4 | 3.0 |
Isoenzymes/biosynthesis | 2 | 4.0 |
Gene Expression Regulation, Developmental | 6 | 0.0 |
Gestational Age | 5 | 0.0 |
Multigene Family | 5 | 0.0 |
Proto-Oncogene Proteins/*chemistry/genetics/metabolism | 2 | 25.0 |
Proto-Oncogene Proteins c-bcl-2/*chemistry/genetics/metabolism | 2 | 100.0 |
Proliferating Cell Nuclear Antigen/biosynthesis | 4 | 8.0 |
Active Transport, Cell Nucleus/drug effects | 2 | 5.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Dyes/pharmacology | 4 | 4.0 |
Genes, Tumor Suppressor/genetics | 4 | 2.0 |
Neoplasms/*therapy | 3 | 2.0 |
Propidium/pharmacology | 2 | 14.0 |
Trypan Blue/pharmacology | 4 | 25.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 2 | 3.0 |
Lymph Nodes/chemistry/pathology | 2 | 9.0 |
Receptors, Estrogen/analysis | 7 | 2.0 |
Receptors, Progesterone/analysis | 6 | 2.0 |
Melanocytes/*metabolism | 2 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/*drug effects | 2 | 100.0 |
Vincristine/therapeutic use | 2 | 5.0 |
Mice, SCID | 4 | 0.0 |
Microinjections | 2 | 0.0 |
Signal Transduction/drug effects | 7 | 1.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 6 | 1.0 |
Androgens/*pharmacology | 2 | 3.0 |
Cell Death/drug effects/radiation effects | 2 | 50.0 |
DNA, Viral/analysis | 2 | 0.0 |
Neovascularization, Pathologic | 2 | 0.0 |
Papillomavirus, Human/genetics | 3 | 7.0 |
Gene Products, tax/*physiology | 3 | 15.0 |
Human T-lymphotropic virus 1/*physiology | 2 | 7.0 |
NF-kappa B/*physiology | 3 | 3.0 |
Gene Expression Regulation | 26 | 0.0 |
Chi-Square Distribution | 7 | 0.0 |
Stomach Neoplasms/*genetics | 6 | 5.0 |
Transcription Factors/*genetics | 5 | 0.0 |
Carbonyl Cyanide m-Chlorophenyl Hydrazone/pharmacology | 2 | 15.0 |
Fluorescent Dyes | 5 | 1.0 |
Oxidation-Reduction | 3 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 9 | 6.0 |
Caspases/genetics | 7 | 29.0 |
*Coronary Artery Bypass | 2 | 2.0 |
Brain/pathology | 6 | 1.0 |
Nerve Tissue Proteins/*biosynthesis/genetics | 2 | 4.0 |
Cell Count | 10 | 1.0 |
Heterozygote | 3 | 0.0 |
Homozygote | 2 | 0.0 |
Cyclooxygenase Inhibitors/*pharmacology | 4 | 11.0 |
Dinoprostone/pharmacology | 2 | 2.0 |
Mitochondria/drug effects/enzymology | 3 | 25.0 |
Proteins/drug effects/metabolism | 2 | 22.0 |
Sulfonamides/*pharmacology | 4 | 9.0 |
Neurons/metabolism/pathology | 4 | 5.0 |
Intracellular Membranes/metabolism | 6 | 3.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 4 | 1.0 |
Muscle, Smooth, Vascular/*cytology/drug effects/metabolism | 2 | 28.0 |
Breast Neoplasms/genetics | 3 | 1.0 |
Prostatic Neoplasms/genetics | 3 | 6.0 |
Proto-Oncogene Proteins/biosynthesis/*genetics/physiology | 2 | 25.0 |
Lymphocytes/*cytology | 3 | 9.0 |
Transforming Growth Factor beta/*metabolism | 2 | 0.0 |
Epidermal Growth Factor/*pharmacology | 2 | 0.0 |
Glutathione/metabolism | 3 | 1.0 |
Prospective Studies | 12 | 0.0 |
Butyrates/*pharmacology | 2 | 4.0 |
Antibodies, Monoclonal/immunology/pharmacology | 2 | 2.0 |
Cytarabine/*pharmacology | 3 | 8.0 |
Codon/genetics | 4 | 1.0 |
Consensus Sequence | 3 | 0.0 |
Cyclins/genetics | 15 | 10.0 |
Substrate Specificity | 6 | 0.0 |
*Transcription Factors | 7 | 0.0 |
Apoptosis/drug effects/genetics | 6 | 16.0 |
Adenocarcinoma/drug therapy/metabolism/pathology | 2 | 28.0 |
Colonic Neoplasms/drug therapy/metabolism/pathology | 3 | 100.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 3 | 3.0 |
Signal Transduction/*drug effects/physiology | 2 | 3.0 |
Paclitaxel/*pharmacology | 4 | 6.0 |
Adenoma/genetics/metabolism | 2 | 18.0 |
Carcinoma/genetics/*metabolism | 2 | 11.0 |
Proto-Oncogene Proteins/*biosynthesis/*genetics | 4 | 28.0 |
Cell Differentiation/physiology | 5 | 1.0 |
DNA Fragmentation/physiology | 3 | 30.0 |
Cisplatin/administration & dosage | 7 | 3.0 |
Etoposide/administration & dosage | 2 | 1.0 |
Receptor, Epidermal Growth Factor/analysis | 3 | 1.0 |
DNA-Binding Proteins/metabolism | 7 | 0.0 |
Serine/metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 6 | 0.0 |
Carcinoma/*genetics/pathology/surgery | 2 | 40.0 |
Glutathione Transferase/metabolism | 4 | 0.0 |
Enzyme Precursors/metabolism | 2 | 1.0 |
Epithelial Cells/*metabolism | 2 | 1.0 |
Lung/*cytology | 2 | 6.0 |
Up-Regulation/physiology | 5 | 4.0 |
Cytochromes c/metabolism | 11 | 16.0 |
Recombinant Proteins/chemistry/metabolism | 4 | 0.0 |
Larynx/pathology | 2 | 16.0 |
Protein p53/*genetics | 15 | 9.0 |
Protein p16/*genetics | 2 | 2.0 |
Gene Expression Regulation/drug effects/physiology | 2 | 3.0 |
Genes, ras/*genetics | 4 | 4.0 |
Apoptosis/genetics/physiology | 3 | 14.0 |
Chromatography, Affinity | 2 | 0.0 |
Protein p53/genetics/*metabolism/physiology | 2 | 40.0 |
Open Reading Frames | 2 | 0.0 |
*Transcription, Genetic | 4 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 4 | 2.0 |
Immunohistochemistry/*methods | 2 | 2.0 |
Proto-Oncogene Proteins/immunology/metabolism | 3 | 60.0 |
Neck | 2 | 3.0 |
Age Factors | 8 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
*Microsatellite Repeats/genetics | 2 | 100.0 |
Sex Factors | 8 | 0.0 |
*Adenoviridae | 2 | 6.0 |
Antineoplastic Agents, Phytogenic/therapeutic use | 3 | 21.0 |
Cisplatin/*therapeutic use | 3 | 9.0 |
Gene Library | 3 | 0.0 |
Models, Genetic | 3 | 0.0 |
DNA Damage/genetics | 5 | 11.0 |
DNA Repair/drug effects | 2 | 6.0 |
Growth Substances/metabolism | 2 | 1.0 |
Neurons/drug effects/*metabolism/pathology | 2 | 20.0 |
Cell Size/drug effects | 3 | 3.0 |
Ultraviolet Rays | 14 | 2.0 |
Metaplasia | 3 | 3.0 |
G1 Phase | 5 | 1.0 |
Leukocytes, Mononuclear/cytology | 2 | 4.0 |
Lymphocyte Activation | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/*physiology | 3 | 60.0 |
Gene Frequency | 4 | 0.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
Sampling Studies | 2 | 1.0 |
Age of Onset | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*metabolism | 4 | 0.0 |
Circular Dichroism | 2 | 0.0 |
Detergents/*pharmacology | 2 | 12.0 |
Gamma Rays | 7 | 3.0 |
Nitric Oxide/*physiology | 2 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/immunology/metabolism | 2 | 50.0 |
Proto-Oncogene Proteins c-bcl-2/drug effects/metabolism | 5 | 41.0 |
Gene Expression Regulation/*drug effects | 5 | 0.0 |
Genes, bcl-2/*drug effects | 4 | 57.0 |
Mutagens/*pharmacology | 2 | 6.0 |
Butyric Acid/*pharmacology | 3 | 30.0 |
T-Lymphocytes/cytology/*drug effects | 2 | 13.0 |
Adenoviridae/*genetics | 10 | 4.0 |
Fibroblasts/cytology/metabolism | 4 | 2.0 |
Cervix Neoplasms/genetics/*metabolism/pathology | 2 | 28.0 |
Organ Specificity | 3 | 0.0 |
Cervix Neoplasms/*metabolism/pathology | 2 | 11.0 |
Enzyme Precursors/biosynthesis/genetics | 2 | 40.0 |
*Genes, Tumor Suppressor | 7 | 0.0 |
Neoplasms/genetics | 2 | 1.0 |
Smoking | 2 | 0.0 |
Histamine Antagonists/*pharmacology | 2 | 25.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
Promoter Regions (Genetics)/physiology | 4 | 2.0 |
Stomach Neoplasms/*genetics/pathology/surgery | 2 | 25.0 |
Carcinoma, Non-Small-Cell Lung/*therapy | 2 | 66.0 |
*Drosophila Proteins | 2 | 0.0 |
Receptors, Retinoic Acid/genetics/*metabolism | 2 | 6.0 |
Tretinoin/*pharmacology | 3 | 0.0 |
Fluorouracil/administration & dosage | 3 | 2.0 |
Cyclin D1/analysis | 4 | 10.0 |
Drug Therapy, Combination | 3 | 0.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Viral Proteins/chemistry | 2 | 33.0 |
Cytoplasm/chemistry | 3 | 1.0 |
Neoplasm Transplantation | 5 | 0.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
Embryo Transfer | 2 | 2.0 |
Fertilization in Vitro | 2 | 1.0 |
Cell Division/*physiology | 3 | 1.0 |
Lung Neoplasms/metabolism/*pathology | 3 | 8.0 |
Membrane Proteins/*physiology | 5 | 3.0 |
Proto-Oncogene Proteins/*physiology | 8 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/*physiology | 6 | 25.0 |
NF-kappa B/biosynthesis | 2 | 13.0 |
Electron Transport Complex IV/metabolism | 2 | 4.0 |
Epithelial Cells | 2 | 0.0 |
Mitochondria, Heart/*metabolism | 2 | 40.0 |
Lymphocytes/*physiology | 2 | 2.0 |
Multidrug Resistance-Associated Proteins | 5 | 6.0 |
Cisplatin/toxicity | 2 | 10.0 |
Colonic Neoplasms | 4 | 2.0 |
Doxorubicin/toxicity | 2 | 9.0 |
Fluorouracil/toxicity | 2 | 40.0 |
Heart Ventricles/metabolism/pathology | 2 | 33.0 |
Myocardium/*pathology | 2 | 5.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Remission Induction | 3 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 5 | 2.0 |
*Point Mutation | 4 | 0.0 |
Cell Death/drug effects | 5 | 3.0 |
Cell Survival/*drug effects | 2 | 2.0 |
Clone Cells | 4 | 0.0 |
Colonic Neoplasms/*pathology | 2 | 2.0 |
Biological Markers/*analysis | 2 | 1.0 |
Microtubule-Associated Proteins/metabolism | 6 | 4.0 |
Neuroglia/metabolism | 2 | 2.0 |
Menstrual Cycle/*physiology | 2 | 3.0 |
Actins/analysis | 2 | 1.0 |
Neoplasm Staging/methods | 2 | 6.0 |
Proto-Oncogene Proteins c-bcl-2 | 21 | 12.0 |
Lipid Peroxidation | 2 | 1.0 |
Tumor Markers, Biological/biosynthesis/*genetics | 2 | 25.0 |
Clinical Trials | 4 | 0.0 |
Cell Nucleus | 2 | 2.0 |
Keratin/analysis | 3 | 1.0 |
ATP-Binding Cassette Transporters/genetics | 2 | 3.0 |
Carrier Proteins/genetics | 4 | 1.0 |
P-Glycoprotein/genetics | 5 | 16.0 |
Carcinoma, Squamous Cell/genetics/*metabolism/pathology | 2 | 8.0 |
Tobacco, Smokeless/*adverse effects | 2 | 25.0 |
Anticarcinogenic Agents/pharmacology | 2 | 7.0 |
Colorectal Neoplasms/genetics/metabolism/*pathology | 2 | 16.0 |
Intracellular Membranes/drug effects/physiology | 2 | 22.0 |
Proto-Oncogenes | 3 | 1.0 |
HIV Seropositivity | 2 | 1.0 |
Genes, Tumor Suppressor/*genetics | 2 | 0.0 |
Radiotherapy/adverse effects | 2 | 5.0 |
Breast Neoplasms/*genetics/pathology | 3 | 1.0 |
Mastectomy | 2 | 2.0 |
Precancerous Conditions/*pathology | 4 | 14.0 |
Colonic Neoplasms/*genetics | 8 | 10.0 |
DNA, Neoplasm/genetics | 11 | 1.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Mutagens/*toxicity | 2 | 1.0 |
Carcinoma, Squamous Cell/*genetics/mortality/*pathology | 2 | 100.0 |
Carrier Proteins/biosynthesis | 10 | 17.0 |
Random Allocation | 3 | 0.0 |
Adenoma/*pathology | 2 | 9.0 |
*Cell Division | 4 | 2.0 |
Colorectal Neoplasms/*pathology | 3 | 5.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Genetic Markers | 8 | 0.0 |
Point Mutation | 10 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 3 | 2.0 |
*Apoptosis/drug effects/radiation effects | 2 | 18.0 |
Antigens, CD/biosynthesis | 4 | 1.0 |
Carcinoma, Hepatocellular/*genetics/*pathology | 2 | 16.0 |
Liver Neoplasms/*genetics/*pathology | 2 | 16.0 |
Protein p16 | 3 | 2.0 |
Retinoblastoma Protein/*genetics | 2 | 4.0 |
Preoperative Care | 4 | 2.0 |
*Body Image | 2 | 66.0 |
Hand/surgery | 2 | 50.0 |
Health Services Research | 2 | 11.0 |
Outcome and Process Assessment (Health Care) | 2 | 9.0 |
*Patient Satisfaction | 2 | 40.0 |
Philosophy, Medical | 2 | 66.0 |
Psychometrics | 2 | 3.0 |
Surgery/*standards | 2 | 66.0 |
*Treatment Outcome | 2 | 8.0 |
*CDC2-CDC28 Kinases | 3 | 0.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Cell Transformation, Viral | 2 | 0.0 |
Cyclin E/metabolism | 2 | 1.0 |
Cyclin-Dependent Kinases/metabolism | 4 | 1.0 |
Cyclins/*genetics | 2 | 1.0 |
Neoplasm Proteins/biosynthesis/*physiology | 2 | 40.0 |
Protein p53/biosynthesis/*physiology | 2 | 28.0 |
Cell Transformation, Neoplastic/genetics | 5 | 1.0 |
*Gene Deletion | 3 | 0.0 |
Korea/epidemiology | 2 | 3.0 |
Oncogenes | 2 | 0.0 |
Antigens, CD95/*analysis | 4 | 19.0 |
Membrane Glycoproteins/*analysis | 2 | 1.0 |
Proliferating Cell Nuclear Antigen/*analysis | 2 | 1.0 |
DNA Fragmentation/*physiology | 3 | 42.0 |
Proto-Oncogene Proteins c-fos/*metabolism | 2 | 5.0 |
Glioma/*genetics | 2 | 2.0 |
Luciferases/metabolism | 4 | 0.0 |
Nuclear Proteins/*metabolism | 7 | 1.0 |
Plasmids | 3 | 0.0 |
beta-Galactosidase/metabolism | 4 | 2.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics | 4 | 4.0 |
Frameshift Mutation/*genetics | 7 | 13.0 |
DNA, Neoplasm/genetics/metabolism | 2 | 2.0 |
Keratinocytes/chemistry/pathology | 2 | 50.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/genetics/*physiology | 2 | 100.0 |
Tumor Markers, Biological/metabolism | 9 | 2.0 |
Cell Death/genetics | 2 | 5.0 |
Blotting, Southern | 5 | 0.0 |
Genes, bcl-2/*physiology | 3 | 37.0 |
Oxidative Stress | 5 | 1.0 |
Reactive Oxygen Species | 5 | 4.0 |
Neoplasm Proteins/*biosynthesis | 4 | 4.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Recurrence | 6 | 0.0 |
Neoplasm Proteins/analysis/*metabolism | 2 | 18.0 |
Protein p53/analysis/metabolism | 2 | 100.0 |
Mitochondria/*pathology | 3 | 42.0 |
Cell Nucleus/metabolism/pathology | 5 | 16.0 |
Receptor, IGF Type 2/*genetics | 5 | 17.0 |
Adenoma/*genetics/pathology | 3 | 11.0 |
Growth Substances/physiology | 2 | 1.0 |
Japan | 2 | 0.0 |
Loss of Heterozygosity/genetics | 2 | 1.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
*Carrier Proteins | 4 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 2 | 1.0 |
*Gene Transfer Techniques | 6 | 1.0 |
Stomach Neoplasms | 2 | 6.0 |
Lac Operon | 4 | 3.0 |
Antigens, CD95/*physiology | 2 | 2.0 |
Indoles/*pharmacology | 2 | 2.0 |
Apoptosis/*genetics/physiology | 2 | 10.0 |
Cell Differentiation/drug effects/*physiology | 2 | 3.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 8 | 3.0 |
Microtubule-Associated Proteins/genetics | 4 | 10.0 |
Nerve Degeneration/*pathology | 2 | 22.0 |
Cyclins/*biosynthesis/genetics | 3 | 8.0 |
Viral Matrix Proteins/biosynthesis | 2 | 33.0 |
Antibodies, Monoclonal/pharmacology | 8 | 1.0 |
Antigens, CD95/biosynthesis/*physiology | 2 | 25.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
India | 3 | 0.0 |
Protein p53/analysis/*metabolism | 2 | 33.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Adenocarcinoma/metabolism/*pathology | 3 | 5.0 |
G1 Phase/drug effects | 4 | 3.0 |
Genes, p53/physiology | 3 | 11.0 |
Proto-Oncogene Proteins/*analysis/metabolism | 2 | 33.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis/metabolism | 2 | 100.0 |
Adenocarcinoma/*genetics | 4 | 2.0 |
Chorionic Gonadotropin/pharmacology | 3 | 2.0 |
Follicle Stimulating Hormone/pharmacology | 3 | 5.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Cell Survival/drug effects/genetics | 2 | 9.0 |
Tumor Cells, Cultured/metabolism/radiation effects | 2 | 22.0 |
Cerebellum/pathology | 2 | 6.0 |
Antineoplastic Agents, Alkylating/pharmacology | 3 | 11.0 |
Keratin/metabolism | 2 | 1.0 |
Neuroglia/pathology | 2 | 9.0 |
Neurons/pathology | 3 | 2.0 |
Endoplasmic Reticulum/metabolism | 3 | 1.0 |
Protein Structure, Quaternary | 2 | 1.0 |
Proto-Oncogene Proteins/chemistry/genetics/metabolism | 2 | 33.0 |
Solubility | 2 | 0.0 |
Chromatin/metabolism | 4 | 1.0 |
Androgens/pharmacology | 2 | 4.0 |
Carrier Proteins/analysis | 6 | 6.0 |
Protein p53/analysis/genetics | 2 | 8.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Membrane Proteins/biosynthesis | 8 | 12.0 |
Genes, cdc | 2 | 4.0 |
Retinoid X Receptors | 2 | 0.0 |
Estrogens | 2 | 8.0 |
Neoplasm Proteins/biosynthesis/physiology | 2 | 66.0 |
Drug Resistance, Neoplasm/*genetics | 4 | 4.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Neoplasms/*metabolism/*pathology | 2 | 15.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics/pathology | 2 | 28.0 |
Phenanthrenes/*pharmacology | 2 | 50.0 |
Cell Nucleus/*metabolism | 3 | 0.0 |
Epithelium/pathology | 3 | 2.0 |
Oncogene Proteins, Fusion/*genetics/metabolism | 2 | 9.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
DNA Damage/*radiation effects | 2 | 18.0 |
Micronucleus Tests | 2 | 4.0 |
Fluorescent Antibody Technique | 6 | 0.0 |
Tumor Cells, Cultured/drug effects/*metabolism | 3 | 13.0 |
Transforming Growth Factor beta/genetics | 4 | 4.0 |
Staining and Labeling/methods | 2 | 1.0 |
Hamsters | 7 | 0.0 |
Melanoma/*pathology | 2 | 3.0 |
Thymidylate Synthase/antagonists & inhibitors | 2 | 10.0 |
Ovarian Neoplasms | 4 | 10.0 |
Bladder Neoplasms/*genetics | 4 | 4.0 |
Carcinoma, Transitional Cell/*genetics | 2 | 6.0 |
Carcinoma/*metabolism/pathology | 3 | 4.0 |
Ovarian Neoplasms/*metabolism/pathology | 4 | 6.0 |
Mouth Neoplasms/*pathology | 2 | 8.0 |
Tumor Virus Infections/*complications | 2 | 7.0 |
Permeability | 7 | 4.0 |
Porins/physiology | 2 | 100.0 |
Amyloid beta-Protein Precursor/genetics | 2 | 4.0 |
Brain/metabolism/*pathology | 2 | 6.0 |
Nerve Degeneration | 3 | 4.0 |
Leukemia/*genetics | 2 | 1.0 |
Cyclin D1/metabolism | 5 | 3.0 |
Melanoma/*metabolism/pathology | 2 | 5.0 |
Receptors, Estrogen/*metabolism | 2 | 0.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Colorectal Neoplasms/genetics | 2 | 4.0 |
Liposomes | 4 | 1.0 |
Molecular Weight | 4 | 0.0 |
Proto-Oncogene Proteins/chemistry/*metabolism | 3 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/chemistry/*metabolism | 2 | 33.0 |
*Hyperthermia, Induced | 2 | 4.0 |
Radiotherapy Dosage | 3 | 2.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Fluorescent Antibody Technique, Direct | 2 | 1.0 |
BRCA2 Protein | 2 | 0.0 |
DNA, Neoplasm | 3 | 2.0 |
Chickens | 2 | 0.0 |
Gene Expression/*drug effects | 4 | 1.0 |
Granulosa Cells/chemistry | 2 | 10.0 |
Ovary/*metabolism | 2 | 3.0 |
Sequence Homology | 2 | 0.0 |
Endocrinology/*history | 2 | 50.0 |
Forecasting | 3 | 0.0 |
History, 21st Century | 2 | 5.0 |
Diagnosis, Differential | 4 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*physiology | 3 | 1.0 |
Colorectal Neoplasms/pathology | 2 | 14.0 |
Proto-Oncogene Proteins c-bcl-2/*pharmacology | 2 | 66.0 |
Endometrium/*pathology | 2 | 10.0 |
Genes, p53/*physiology | 5 | 11.0 |
Drug Industry | 3 | 16.0 |
Oligonucleotide Array Sequence Analysis | 6 | 0.0 |
Craniocerebral Trauma/genetics/*pathology | 2 | 100.0 |
Gene Expression Regulation/genetics | 4 | 2.0 |
Choriocarcinoma/genetics/*pathology | 2 | 66.0 |
Hydatidiform Mole/genetics/*pathology | 2 | 100.0 |
Trophoblastic Tumor, Placental Site/genetics/*pathology | 2 | 100.0 |
Uterine Neoplasms/genetics/*pathology | 2 | 66.0 |
Lymphocytes/metabolism/*pathology | 2 | 28.0 |
Wiskott-Aldrich Syndrome/metabolism/*pathology | 2 | 100.0 |
Caspases/*physiology | 4 | 18.0 |
T-Lymphocytes/*pathology/*physiology/virology | 2 | 100.0 |
Carcinoma, Merkel Cell/diagnosis/*metabolism/pathology/therapy | 2 | 100.0 |
Skin Neoplasms/diagnosis/*metabolism/pathology/therapy | 2 | 100.0 |
Osteosarcoma/*genetics/physiopathology | 2 | 66.0 |
Point Mutation/genetics/*physiology | 2 | 33.0 |
Radiation Tolerance/*genetics | 2 | 3.0 |
Radiobiology | 2 | 15.0 |
Tumor Cells, Cultured/radiation effects | 3 | 7.0 |
Gene Expression/*genetics | 4 | 3.0 |
Annexin A5/analysis | 2 | 9.0 |
Leukemia/*metabolism/*pathology | 2 | 66.0 |
DNA/*metabolism | 3 | 0.0 |
CD40 Ligand | 2 | 1.0 |
Cell Survival/genetics | 3 | 5.0 |
DNA, Complementary | 4 | 0.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Breast Neoplasms/genetics/*metabolism/pathology | 4 | 9.0 |
Breast Neoplasms/*genetics | 3 | 0.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Glioma/*metabolism/*pathology | 3 | 30.0 |
Transfection/genetics | 3 | 2.0 |
Lasers | 2 | 1.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Cytoskeletal Proteins/genetics | 2 | 3.0 |
Carcinoma, Small Cell/genetics | 2 | 5.0 |
Carcinoma, Squamous Cell/genetics | 2 | 3.0 |
*Loss of Heterozygosity | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Brain Neoplasms/*metabolism/*pathology | 2 | 18.0 |
Glioblastoma/pathology | 2 | 11.0 |
Antineoplastic Agents/pharmacology/*therapeutic use | 2 | 5.0 |
Ionomycin/*pharmacology | 2 | 14.0 |
Ionophores/*pharmacology | 2 | 10.0 |
Aorta/cytology | 2 | 2.0 |
Culture Media | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Animals, Genetically Modified | 2 | 0.0 |
*Genes, myc | 2 | 0.0 |
Mice, Inbred CBA | 3 | 0.0 |
Alzheimer Disease/*metabolism | 4 | 1.0 |
Tissue Distribution/physiology | 2 | 6.0 |
Herpesvirus 4, Human/genetics | 2 | 2.0 |
Protein p53/biosynthesis/*genetics | 2 | 13.0 |
RNA, Viral/genetics | 2 | 2.0 |
Antigens, CD/analysis | 3 | 0.0 |
Hormone Antagonists/*pharmacology | 2 | 8.0 |
Luteal Phase | 2 | 3.0 |
Mifepristone/*pharmacology | 3 | 12.0 |
Preoperative Care/methods | 2 | 7.0 |
Carcinogens | 2 | 2.0 |
Proto-Oncogene Proteins c-myc/metabolism | 3 | 3.0 |
*Multigene Family | 2 | 0.0 |
Carcinoma, Squamous Cell/*pathology | 4 | 4.0 |
Cytotoxicity, Immunologic | 3 | 0.0 |
Exons/genetics | 3 | 0.0 |
DNA Replication | 3 | 0.0 |
Kidney Neoplasms/*genetics | 2 | 0.0 |
Protein Kinases/metabolism | 2 | 0.0 |
G1 Phase/*drug effects | 3 | 3.0 |
*Repressor Proteins | 5 | 0.0 |
Retinoids/*pharmacology | 2 | 3.0 |
Adenocarcinoma/*metabolism/pathology | 4 | 3.0 |
*Down-Regulation | 3 | 0.0 |
Trans-Activation (Genetics)/*genetics | 2 | 2.0 |
Proteins/*genetics | 3 | 0.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 2 | 1.0 |
Up-Regulation/*physiology | 2 | 4.0 |
Epithelium/metabolism/pathology | 3 | 4.0 |
Thiazolidinediones/pharmacology | 2 | 12.0 |
Proto-Oncogene Proteins/metabolism/physiology | 2 | 13.0 |
Glioma | 2 | 2.0 |
Membrane Glycoproteins/*physiology | 3 | 1.0 |
Membrane Proteins/*genetics | 4 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 3 | 6.0 |
Deoxycytidine/*analogs & derivatives/pharmacology | 3 | 12.0 |
Pancreatic Neoplasms/metabolism/*pathology | 2 | 6.0 |
Lung Neoplasms/*genetics/pathology | 3 | 3.0 |
Lung Neoplasms/pathology | 2 | 3.0 |
Prostatic Neoplasms/pathology | 2 | 8.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Gastrointestinal Neoplasms/*genetics/pathology | 2 | 11.0 |
Protein Hybridization | 3 | 5.0 |
Stem Cell Factor/pharmacology | 2 | 1.0 |
Mouth Mucosa/metabolism | 2 | 11.0 |
Biological Transport/physiology | 2 | 1.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Genetic Screening | 2 | 0.0 |
Cell Line, Tumor/drug effects | 3 | 13.0 |
HIV-1/*physiology | 2 | 0.0 |
Antigens, CD95/*biosynthesis/genetics | 2 | 28.0 |
Colonic Neoplasms/metabolism | 2 | 3.0 |
Microscopy, Phase-Contrast | 2 | 2.0 |
Caspase 1/genetics | 2 | 100.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Chromosomes, Human, Pair 14 | 2 | 1.0 |
Chromosomes, Human, Pair 18 | 2 | 1.0 |
Homeostasis | 2 | 0.0 |
Leukemia, Lymphocytic, Acute, L1/*genetics/pathology | 2 | 33.0 |
Neoplasm Proteins/analysis/genetics | 3 | 12.0 |
Keratinocytes/chemistry | 2 | 11.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis/immunology | 2 | 100.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
Protein p53/genetics/metabolism/*physiology | 2 | 33.0 |
Leukemia, Myeloid/*pathology | 3 | 5.0 |
*Protein Conformation | 2 | 0.0 |
Dipeptides/pharmacology | 2 | 4.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Apoptosis/*drug effects/*radiation effects | 4 | 40.0 |
Cell Survival/drug effects/radiation effects | 2 | 4.0 |
DNA Fragmentation/drug effects/radiation effects | 3 | 100.0 |
G1 Phase/radiation effects | 3 | 37.0 |
X-Rays | 3 | 2.0 |
Breast Neoplasms/metabolism/mortality/*pathology | 2 | 40.0 |
Receptors, Estrogen/biosynthesis | 2 | 4.0 |
Receptors, Progesterone/biosynthesis | 2 | 6.0 |
G2 Phase | 4 | 2.0 |
Mitosis | 2 | 0.0 |
Leukemia, B-Cell, Chronic/*metabolism | 2 | 16.0 |
Ovarian Neoplasms/*drug therapy/metabolism | 2 | 15.0 |
Antioxidants/*pharmacology | 2 | 1.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
*Tumor Markers, Biological | 2 | 1.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
*DNA Methylation | 2 | 0.0 |
Cell Survival/radiation effects | 2 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis/physiology | 3 | 75.0 |
S Phase/radiation effects | 2 | 14.0 |
Recombinant Proteins | 2 | 0.0 |
Cytochrome c Group/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Proto-Oncogene Proteins/antagonists & inhibitors/*metabolism | 2 | 7.0 |
Skin Neoplasms/*metabolism/pathology | 4 | 6.0 |
Adenocarcinoma/*chemistry/pathology | 3 | 6.0 |
Cell Division/drug effects/radiation effects | 3 | 12.0 |
Ultraviolet Rays/adverse effects | 2 | 3.0 |
Adenovirus E1B Proteins/genetics/*metabolism | 2 | 33.0 |
Intracellular Membranes/*physiology | 4 | 36.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Epithelium/metabolism | 5 | 1.0 |
Microtubule-Associated Proteins/*biosynthesis | 2 | 9.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Disease Susceptibility | 3 | 0.0 |
S Phase | 3 | 0.0 |
Enzyme Precursors/biosynthesis | 2 | 22.0 |
Breast Neoplasms/genetics/*pathology | 2 | 4.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
*Oncogenes | 2 | 0.0 |
DNA, Neoplasm/*analysis | 3 | 1.0 |
Proto-Oncogene Proteins c-fos/genetics | 2 | 3.0 |
*Proto-Oncogenes | 4 | 0.0 |
Cell Cycle/drug effects/genetics | 2 | 11.0 |
Neuroblastoma/pathology | 2 | 6.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/pathology | 2 | 7.0 |
Neoplasm Proteins/genetics/*physiology | 2 | 4.0 |
Neuroblastoma/*genetics | 2 | 2.0 |
Mitochondria/pathology | 2 | 15.0 |
*Chromosome Mapping | 2 | 0.0 |
Carcinoma, Basal Cell/*metabolism/pathology | 2 | 20.0 |
Epidermis/metabolism | 2 | 5.0 |
Alanine/genetics | 2 | 1.0 |
Cysteine Proteinase Inhibitors/*pharmacology | 2 | 6.0 |
Proto-Oncogene Proteins/chemistry/genetics/*metabolism | 4 | 7.0 |
Interferon-alpha/*pharmacology | 2 | 1.0 |
Cyclosporine/pharmacology | 2 | 0.0 |
Glioma/*pathology | 2 | 3.0 |
HT29 Cells | 3 | 1.0 |
Carcinoma, Squamous Cell/*genetics/metabolism/pathology | 2 | 9.0 |
Butyric Acid | 5 | 10.0 |
Butyric Acids/pharmacology | 3 | 9.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
CHO Cells | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/chemistry/genetics/*metabolism | 3 | 60.0 |
Cell Cycle/physiology | 5 | 1.0 |
Carrier Proteins/analysis/metabolism | 2 | 33.0 |
Membrane Proteins/analysis/metabolism | 2 | 20.0 |
Prevalence | 3 | 0.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
Carcinoma/*metabolism | 2 | 2.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 2 | 3.0 |
Leukocytes, Mononuclear/metabolism | 3 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/genetics/metabolism/*physiology | 2 | 66.0 |
Lung Neoplasms/genetics/*metabolism/pathology | 2 | 7.0 |
DNA Replication/genetics | 2 | 3.0 |
DNA, Neoplasm/*metabolism | 2 | 6.0 |
*Caspases | 5 | 8.0 |
Cysteine Endopeptidases/metabolism | 4 | 1.0 |
Proto-Oncogene Proteins/*chemistry/*metabolism | 3 | 17.0 |
Carcinogens/pharmacology | 2 | 2.0 |
Mammals | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors/metabolism | 2 | 100.0 |
Yeasts/genetics | 3 | 3.0 |
Colorectal Neoplasms/*genetics/*pathology | 2 | 8.0 |
*DNA Replication | 2 | 0.0 |
Membrane Proteins/*chemistry/metabolism | 2 | 9.0 |
Peptide Fragments/chemistry/metabolism | 2 | 1.0 |
Skin Neoplasms/*pathology | 2 | 2.0 |
Bone Marrow/chemistry | 2 | 6.0 |
Biotin | 2 | 3.0 |
Deoxyuracil Nucleotides | 2 | 40.0 |
*Cell Cycle | 3 | 1.0 |
Butyric Acids/*pharmacology | 2 | 8.0 |
DNA Probes | 2 | 0.0 |
DNA, Neoplasm/drug effects | 2 | 6.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/drug effects | 2 | 40.0 |
Proto-Oncogene Proteins/*chemistry/metabolism | 2 | 10.0 |
3T3 Cells | 4 | 0.0 |
Luminescent Proteins/genetics/*metabolism | 2 | 18.0 |
Mitochondria/genetics/*metabolism | 2 | 20.0 |
PC12 Cells | 3 | 0.0 |
Proto-Oncogene Proteins/*genetics/physiology | 2 | 8.0 |
DNA Topoisomerases, Type II/*antagonists & inhibitors | 4 | 16.0 |
Leukemia, Promyelocytic, Acute/*drug therapy/pathology | 2 | 22.0 |
Oxidative Stress/drug effects | 2 | 4.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Antineoplastic Agents/therapeutic use | 6 | 2.0 |
*Circadian Rhythm | 2 | 0.0 |
*Photochemotherapy | 2 | 4.0 |
Protein Biosynthesis/drug effects | 2 | 3.0 |
Drug Administration Schedule | 2 | 0.0 |
Proto-Oncogenes/*genetics | 4 | 5.0 |
RNA/metabolism | 3 | 0.0 |
Caspase 1 | 6 | 15.0 |
Signal Transduction/genetics/physiology | 2 | 4.0 |
Gene Expression Regulation, Leukemic | 2 | 2.0 |
Alzheimer Disease/*metabolism/pathology | 2 | 2.0 |
Culture Media, Serum-Free | 5 | 1.0 |
Insulin/pharmacology | 2 | 0.0 |
Insulin-Like Growth Factor I/pharmacology | 2 | 1.0 |
Interleukin-3/*pharmacology | 2 | 1.0 |
Saccharomyces cerevisiae/growth & development/metabolism | 2 | 40.0 |
DNA, Neoplasm/metabolism | 3 | 2.0 |
Electrophoresis | 2 | 0.0 |
Brain Chemistry | 2 | 0.0 |
Gene Expression/genetics | 2 | 0.0 |
Cysteine Endopeptidases | 4 | 8.0 |
Receptors, Tumor Necrosis Factor/immunology | 2 | 9.0 |
Plant Extracts/chemistry/*pharmacology | 2 | 22.0 |
Cytokines/biosynthesis/genetics | 2 | 3.0 |
Cell Fractionation | 2 | 0.0 |
*DNA Repair Enzymes | 2 | 2.0 |
Mice, Mutant Strains | 2 | 0.0 |
*Cell Transformation, Viral | 2 | 1.0 |
DNA, Viral/biosynthesis | 2 | 3.0 |
Fibroblasts | 3 | 0.0 |
Protein p53/biosynthesis/*metabolism | 2 | 28.0 |
RNA Polymerase II/antagonists & inhibitors | 2 | 33.0 |
Cell Culture Techniques | 4 | 0.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
Catalase/metabolism | 2 | 3.0 |
Hippocampus/*metabolism/pathology | 2 | 5.0 |
T-Lymphocytes/*physiology | 2 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 2 | 0.0 |
Lung Neoplasms | 2 | 1.0 |
Prostatic Neoplasms/*drug therapy/*pathology | 3 | 27.0 |
Endothelial Growth Factors/pharmacology | 2 | 1.0 |
Cell Cycle/*genetics/radiation effects | 2 | 28.0 |
DNA Topoisomerases, Type I/*antagonists & inhibitors | 5 | 16.0 |
*Bile Ducts, Intrahepatic | 2 | 6.0 |
*Depsipeptides | 2 | 6.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
RNA Interference | 3 | 1.0 |
Cell Compartmentation | 3 | 0.0 |
Apoptosis/*physiology/radiation effects | 2 | 25.0 |
Proto-Oncogene Proteins/biosynthesis/*physiology | 2 | 12.0 |
Receptors, Retinoic Acid/metabolism | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/*genetics | 6 | 3.0 |
Camptothecin/*analogs & derivatives/pharmacology | 2 | 20.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
G1 Phase/genetics | 2 | 6.0 |
Membrane Proteins/chemistry/genetics/*metabolism | 3 | 4.0 |
Cervix Neoplasms/*genetics/pathology/virology | 2 | 22.0 |
Papillomavirus, Human | 2 | 5.0 |
Mouth Mucosa/chemistry/pathology | 2 | 33.0 |
Endometriosis/*metabolism/pathology | 2 | 12.0 |
Keratinocytes/metabolism | 2 | 1.0 |
Zinc Fingers | 2 | 0.0 |
Cell Cycle Proteins/analysis | 2 | 7.0 |
DNA-Binding Proteins/analysis | 2 | 2.0 |
Transcription Factors/analysis | 2 | 2.0 |
Mice, Inbred NOD | 2 | 0.0 |
Cell Cycle/drug effects/*physiology | 2 | 4.0 |
Lung Neoplasms/*chemistry/pathology | 2 | 11.0 |
Paclitaxel/*toxicity | 2 | 100.0 |
Vincristine/toxicity | 2 | 28.0 |
Neoplasms/*genetics | 2 | 0.0 |
Cadaver | 3 | 1.0 |
Myocardium/*metabolism/pathology | 2 | 7.0 |
Parity | 2 | 1.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Nuclear Proteins/*analysis | 2 | 1.0 |
P-Glycoprotein/biosynthesis | 2 | 9.0 |
Colorectal Neoplasms/*genetics/metabolism | 3 | 9.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Proto-Oncogene Proteins/drug effects/*metabolism | 4 | 57.0 |
Up-Regulation/genetics | 2 | 2.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
Leukocytes, Mononuclear/chemistry | 2 | 7.0 |
Mitogen-Activated Protein Kinases/drug effects/metabolism | 2 | 4.0 |
*DNA Helicases | 2 | 0.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Acetylation | 2 | 0.0 |
DNA Damage/radiation effects | 2 | 9.0 |
Gene Expression Regulation, Neoplastic/radiation effects | 2 | 15.0 |
Gene Targeting | 2 | 0.0 |
Proteins/*physiology | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/*chemistry | 2 | 100.0 |
Protein Transport/drug effects | 2 | 3.0 |
Colorectal Neoplasms/genetics/pathology | 2 | 11.0 |
HCT116 Cells | 2 | 8.0 |
Organoplatinum Compounds/*pharmacology | 2 | 12.0 |
Cell Survival/drug effects/physiology | 3 | 3.0 |
RNA, Small Interfering/genetics | 2 | 1.0 |
Lung Neoplasms/*drug therapy | 2 | 4.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
S100 Proteins/analysis | 2 | 1.0 |
Vimentin/analysis | 3 | 1.0 |
Gene Expression Profiling/methods | 2 | 2.0 |
Liposomes/metabolism | 3 | 5.0 |
Leukemia, Myelocytic, Acute/pathology | 2 | 12.0 |
Cell Cycle Proteins/biosynthesis | 3 | 11.0 |
cdc25 Phosphatase/biosynthesis | 2 | 40.0 |
DNA Damage/drug effects | 2 | 4.0 |
*Diet | 2 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Neutrophils/*physiology | 3 | 2.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Mitochondria/metabolism/physiology | 2 | 25.0 |
Cell Death/drug effects/physiology | 3 | 7.0 |
Cell Respiration/drug effects/physiology | 2 | 50.0 |
Signal Transduction/drug effects/physiology | 7 | 2.0 |
Estrogen Receptor alpha | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*genetics/metabolism | 4 | 28.0 |
Nitric-Oxide Synthase/*metabolism | 2 | 2.0 |
Caspases/drug effects/*metabolism | 2 | 33.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 2 | 4.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Proto-Oncogene Proteins/*deficiency/metabolism | 2 | 100.0 |
Arthritis, Rheumatoid/*immunology | 2 | 0.0 |
RNA, Messenger/genetics/*metabolism | 2 | 1.0 |
Clinical Trials, Phase III | 2 | 4.0 |
Receptor, erbB-2/*metabolism | 2 | 1.0 |
Protein p53/deficiency/genetics | 2 | 50.0 |
Cyclins/drug effects | 2 | 66.0 |
Longitudinal Studies | 2 | 0.0 |
Living Donors | 2 | 4.0 |
Superoxide Dismutase/metabolism | 3 | 3.0 |
Endoplasmic Reticulum/*physiology | 2 | 25.0 |
Cell-Free System | 2 | 0.0 |
Fatty Acid Desaturases/metabolism | 2 | 5.0 |
Proto-Oncogene Proteins c-jun/metabolism | 2 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 5 | 0.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 2 | 1.0 |
Enzyme Activation/drug effects/physiology | 2 | 3.0 |
Neurons/*metabolism | 3 | 1.0 |
Mutation, Missense | 2 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Endoplasmic Reticulum/*metabolism | 2 | 1.0 |
Annexin A5/pharmacology | 2 | 5.0 |
Dactinomycin/*analogs & derivatives/pharmacology | 2 | 66.0 |
Fluorescent Dyes/pharmacology | 3 | 15.0 |
Endometrium/*metabolism/pathology | 2 | 20.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Mitochondria/drug effects | 2 | 12.0 |
Thiazoles/pharmacology | 2 | 1.0 |
Cytochrome c Group/*secretion | 2 | 66.0 |
Membrane Proteins/chemistry/metabolism | 2 | 6.0 |
Graft Survival/*physiology | 2 | 10.0 |
Transplantation, Homologous | 3 | 0.0 |
5' Untranslated Regions/*genetics | 2 | 4.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Neoadjuvant Therapy | 2 | 5.0 |
Membrane Glycoproteins/genetics/*metabolism | 3 | 1.0 |
Cytochrome c Group/drug effects/metabolism | 2 | 50.0 |
Membrane Proteins/drug effects/*metabolism | 2 | 50.0 |
Molecular Structure | 2 | 0.0 |
Genes, bcl-2/drug effects | 3 | 50.0 |
Cyclin D1/*metabolism | 2 | 3.0 |
RNA, Messenger/drug effects/genetics/metabolism | 2 | 2.0 |
Cyclosporine/*pharmacology | 2 | 1.0 |
Cell Proliferation/drug effects | 3 | 3.0 |
Tumor Necrosis Factor-alpha/genetics/*metabolism | 2 | 3.0 |
Protein Synthesis Inhibitors/*pharmacology | 2 | 6.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
Chromosomes, Human, Pair 18/genetics | 2 | 4.0 |
Observer Variation | 2 | 1.0 |
Isoenzymes/*antagonists & inhibitors | 2 | 6.0 |
Proto-Oncogene Proteins/*antagonists & inhibitors/chemistry/metabolism | 2 | 66.0 |
Receptors, Tumor Necrosis Factor/biosynthesis | 2 | 11.0 |
Mitochondria/drug effects/*metabolism | 2 | 12.0 |
Chromosomes, Human, Pair 14/genetics | 2 | 2.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Isoenzymes/*biosynthesis | 2 | 3.0 |
Prostaglandin-Endoperoxide Synthase/*biosynthesis | 2 | 4.0 |
Genes, p16 | 2 | 2.0 |
Protein p16/genetics | 2 | 2.0 |
p14ARF Protein/genetics | 2 | 9.0 |
Caspases/drug effects/metabolism | 2 | 14.0 |
Leukemia, B-Cell, Chronic/*pathology | 2 | 11.0 |
Multienzyme Complexes/*antagonists & inhibitors | 3 | 16.0 |
Carcinoma/*physiopathology | 2 | 22.0 |
Membrane Potentials/drug effects/physiology | 2 | 2.0 |
Neoplasm Proteins/biosynthesis/*genetics | 2 | 2.0 |
14-3-3 Proteins | 2 | 1.0 |
Ovarian Neoplasms/pathology | 2 | 6.0 |
Calpain/*physiology | 2 | 40.0 |
Emodin/*pharmacology | 2 | 40.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 2 | 2.0 |
Cytochrome c Group/physiology | 2 | 50.0 |
